Intracerebral administration of Interleukin-12 (IL-12) and IL-18 modifies the course of mouse scrapie

BACKGROUND: Prion diseases are characterised by a neurodegenerative pattern in which the function of immune system remains still elusive. In the present study, we evaluate if an exogenous treatment with Interleukin-12 (IL-12) and IL-18, able to activate microglia, is able to affect scrapie pathogenesis. RESULTS: Cytokines injected intracranially, induced a strong inflammatory response characterised by TNF-α production and microglia activation. Two groups of mice were injected intracerebrally with high dose of ME7 strain of scrapie containing IL-12 and IL-18 or sterile saline. Cytokines-treated mice showed a more pronounced accumulation of PrP(Sc )in brain tissues at 90 days post-inoculation and a shorter mean survival times than untreated mice. CONCLUSION: We can conclude that intracerebral administration of IL-12 and IL-18 can modulate scrapie pathogenesis possibly through a microglia-mediated pattern

Inter-society consensus for the use of inhaled corticosteroids in infants, children and adolescents with airway diseases

Background: In 2019, a multidisciplinary panel of experts from eight Italian scientific paediatric societies developed a consensus document for the use of inhaled corticosteroids in the management and prevention of the most common paediatric airways disorders. The aim is to provide healthcare providers with a multidisciplinary document including indications useful in the clinical practice. The consensus document was intended to be addressed to paediatricians who work in the Paediatric Divisions, the Primary Care Services and the Emergency Departments, as well as to Residents or PhD students, paediatric nurses and specialists or consultants in paediatric pulmonology, allergy, infectious diseases, and ear, nose, and throat medicine. Methods: Clinical questions identifying Population, Intervention(s), Comparison and Outcome(s) were addressed by methodologists and a general agreement on the topics and the strength of the recommendations (according to the GRADE system) was obtained following the Delphi method. The literature selection included secondary sources such as evidence-based guidelines and systematic reviews and was integrated with primary studies subsequently published. Results: The expert panel provided a number of recommendations on the use of inhaled corticosteroids in preschool wheezing, bronchial asthma, allergic and non-allergic rhinitis, acute and chronic rhinosinusitis, adenoid hypertrophy, laryngitis and laryngospasm. Conclusions: We provided a multidisciplinary update on the current recommendations for the management and prevention of the most common paediatric airways disorders requiring inhaled corticosteroids, in order to share useful indications, identify gaps in knowledge and drive future research

Synergistic Antibiofilm Effects of Exopolymers Produced by the Marine, Thermotolerant <i>Bacillus licheniformis</i> B3-15 and Their Potential Medical Applications

The exopolysaccharide (EPS B3-15) and biosurfactant (BS B3-15), produced by the marine Bacillus licheniformis B3-15, were recently reported to possess different antibiofilm activities, with the EPS being more active in preventing the adhesion of Pseudomonas aeruginosa and Staphylococcus aureus and the BS in destroying their preformed biofilms on different surfaces. In this study, the synergistic effects of the two exopolymers on the bacterial adhesion and biofilm disruption of P. aeruginosa and S. aureus were evaluated on polystyrene, a medical polyvinyl chloride (PVC) device, and contact lenses (CLs) in order to address their potential use in biomedical applications. To this purpose, EPS B3-15 and BS B3-15 were equally combined (1:1 w/w), and the mixture (BPS B3-15) was added at different concentrations (from 50 to 300 µg mL−1) and at different times of bacterial development. Compared to each polymer, the BPS B3-15 (300 µg mL−1) more efficiently reduced the adhesion of P. aeruginosa and S. aureus on polystyrene (65 and 58%, respectively), PVC devices (62 and 42%, respectively), and CLs (39 and 35%, respectively), also in combination with a CLs care solution (88 and 39%, respectively). Furthermore, BPS B3-15 was able to disrupt mature biofilms, acting more effectively against S. aureus (72%) than P. aeruginosa (6%). The combination of exopolymers at low concentrations exhibited synergistic effects to prevent and eradicate biofilms

CONSENSUS INTERSOCIETARIA - L’uso dei corticosteroidi inalatori in età evolutiva

Questo documento è frutto di una collaborazione tra operatori di tutte le aree e affronta il tema dell’impiego appropriato degli steroidi inalatori. Un progetto ambizioso che ha incontrato non poche difficoltà e che non è in grado di dare risposte definitive a tutto, ovviamente, ma ha moltissimi pregi. Innanzitutto la chiarezza della definizione dei contesti clinici in cui si possono utilizzare i corticosteroidi inalatori; ad esempio, wheezing (bronchite asmatiforme) ed asma prescolare nel documento sono dichiaratamente sinonimi per semplificarne l’approccio e questo è certamente arbitrario. Ovviamente wheezing ed asma non sono affatto sinonimi, ma la definizione di asma a questa età è particolarmente difficile, implica una storia e un assetto clinico-immunologico particolare, mentre il documento è e deve essere uno strumento agile che consente di affrontare il sintomo indipendentemente dalla diagnosi precisa che scaturirà dalla osservazione prospettica del bambino. In questa ottica, le differenze tra asma e wheezing sfumano. Il secondo punto di forza è rappresentato dalla ampia e approfondita disanima della letteratura con un approccio estremamente rigoroso che ha consentito di trarre messaggi chiari ove le evidenze convergevano e messaggi invece di minor forza laddove le diverse linee guida (o i dati della letteratura) non davano indicazioni univoche o addirittura davano indicazioni discordantiUn ultimo punto, non certo di minor rilievo, è rappresentato dalla sintesi dei dosaggi degli steroidi che sono riportati nei foglietti illustrativi e i dosaggi indicati dalle maggiori linee guida. Nessun documento ad oggi ha affrontato specificamente un argomento tanto delicato e davvero un grande impegno è stato profuso nella sua realizzazione. Infine va sottolineato lo sforzo per focalizzare solo l’impiego dei corticostreroidi inalatori, resistendo alla tentazione di aggiungere indicazioni per farmaci diversi dagli steroidi. Non è un documento sulla terapia dell’asma e dello wheezing, della rinite, della rinosinusite, adenoidite e laringite, ma solo un documento che sottolinea e supporta le indicazioni, non indicazioni, dosi e molecola di steroide più indicata in quella situazione clinica sulla base dei dati EBM e indipendentemente dall’impiego di altri farmaci

Correction: Inter-society consensus for the use of inhaled corticosteroids in infants, children and adolescents with airway diseases

no abstracy